BSE · 532660 · Pharmaceuticals
Vivimed Labs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹8 Cr with net profit ₹-142 Cr — a -1882.12% net margin, versus -142.48% the period before.
Shareholding
As of 2026-03-31
- Promoter7.57%
- Public90.78%
- FII1.64%
47,492 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.6× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — IBC. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 5.6× (₹5 to ₹27.99) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #79 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,83,298 Cr | 38.89 | 5.78 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,109 Cr | 214.61 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,139 Cr | 20.64 | 4.14 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,414 Cr | 19.59 | 4.96 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,189 Cr | 53.21 | 6.58 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,251 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,286 Cr | 430.79 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,260 Cr | 100.16 | 2.43 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,718 Cr | 294.94 | 5.04 | 16.66% | 15.65% |
| Biocon Ltd. | ₹68,613 Cr | 535.82 | 2.02 | 1.14% | 2.3% |
| Vivimed Labs Ltd.(this company) | ₹43 Cr | — | — | 83.81% | -252.12% |
AI analysis
AI-generated · google/gemini-2.5-flashVivimed Labs Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 43 Cr. The company reported a negative profit margin of -252.12% and revenue growth of -22%. The book value per share is -Rs 29.98. Promoter holding stands at 7.5726%, with 15.18% of this pledged.
Positives
- +The company has a low debt-to-equity ratio of 0.
Negatives
- −The company reported a negative profit margin of -252.12%.
- −Revenue growth was negative at -22%.
- −The book value per share is negative at -Rs 29.98.
- −Promoter shareholding has decreased from 36.6367% in March 2018 to 7.5726% in March 2026.
- −15.18% of promoter shares are pledged.
Financial Performance
The company's revenue declined by -22%. Vivimed Labs Ltd. reported an annual revenue of Rs 7.55 Cr for Mar 2026, a decrease from Rs 120.64 Cr in Mar 2025. The net profit for Mar 2026 was -Rs 142.1 Cr, down from -Rs 31.961 Cr in Mar 2025. Quarterly revenue for Mar 2026 was Rs 12 Cr, with a net loss of -Rs 147.12 Cr.
Profitability & Returns
Vivimed Labs Ltd. recorded a negative profit margin of -252.12%. The company's EPS for Mar 2025 was -3.74, and for Mar 2026 it was 0. Return on capital employed (ROCE) is 0%, while return on equity (ROE) is 83.81%. The annual EBITDA for Mar 2026 was -Rs 141.31 Cr.
Balance Sheet
The company has a negative book value of -Rs 29.98 per share. Vivimed Labs Ltd. has a debt-to-equity ratio of 0. The company's market capitalization is Rs 43 Cr.
Ownership & Pledges
As of March 31, 2026, promoter holding in Vivimed Labs Ltd. stood at 7.5726%. Public shareholding was 90.6676%, and FII holding was 1.6438%. Approximately 15.18% of the promoter's shares are pledged. This includes 299154 shares pledged by Subhash Varalwar, 79000 by Varalwar Sandeep, 400000 by Manohar Rao Varalwar, 150000 by Mamatha Gurnukar, and 25000 by Sujatha Varalwar.
Regulatory & Surveillance
Vivimed Labs Ltd. is under the IBC surveillance measure, indicating regulatory scrutiny. This measure is associated with the Insolvency and Bankruptcy Code.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.